Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial (Lancet Gastroenterology and Hepatology, 2017)

(untitled) - Adams, R; Brown, E; Brown, L; Butler, R; Falk, S; Fisher, D; Kaplan, R; Quirke, P; Richman, S; Samuel, L; Seligmann, J; Seymour, M; et al.